Skip to content

Study · Observational study · n = 245 · 2015

8 results

ROOTS: A multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza®) in type 2 diabetic patients.

Buysschaert M, D'Hooge D, Preumont V

Diabetes & metabolic syndrome8 May 2015Cited by 18 (Europe PMC)

PMID26004030 (opens in a new tab)DOI10.1016/j.dsx.2015.05.001 (opens in a new tab)PepBankPUB-26004030
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes on dual therapy, 66.5% of patients on liraglutide achieved the primary endpoint of improved glycaemic control after 12 months.

    In plain wordsIn adults with type 2 diabetes, about two thirds on liraglutide had clearly improved blood sugar control after 12 months.

    Peptide
    Liraglutide
    Outcome
    Not applicableImproved glycaemic control (HbA1c <7% or decrease of 1% or more)
    Study

    n = 245

    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Patients achieving primary endpoint
    66.5%
    liraglutide

    Source sentences

    Summary
    The primary endpoint was achieved in 66.5% of patients.
    3 context sentences
    Summary · context
    The primary endpoint was to estimate the proportion of patients achieving improved glycaemic control defined as a HbA1c<7% or with a decrease of ≥1% after 12 months.
    Summary · context
    The study included 245 subjects.
    Summary · context
    They received liraglutide in addition to their usual dual therapy (metformin and sulfonylureas or pioglitazone).
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes on dual therapy, HbA1c decreased significantly during one year of liraglutide in routine care.

    In plain wordsIn adults with type 2 diabetes, HbA1c fell during one year of liraglutide in routine care.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change after one year
    Study

    n = 245

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    HbA1c
    9.12%
    baseline
    HbA1c
    7.54%
    after one year

    Source sentences

    Summary
    HbA1c decreased from 9.12%±1.28 at baseline to 7.54%±1.12 after one year follow-up (p<0.001).
    2 context sentences
    Summary · context
    The study included 245 subjects.
    Summary · context
    They received liraglutide in addition to their usual dual therapy (metformin and sulfonylureas or pioglitazone).
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes on dual therapy, BMI decreased significantly during one year of liraglutide in routine care.

    In plain wordsIn adults with type 2 diabetes, BMI fell during one year of liraglutide in routine care.

    Peptide
    Liraglutide
    Outcome
    DecreaseBMI change
    Study

    n = 245

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    BMI
    33.9 kg/m(2)
    baseline
    BMI
    32.8 kg/m(2)
    after one year

    Source sentences

    Summary
    In parallel, we observed a reduction of BMI from baseline 33.9±6.2 to 32.8±6.3 kg/m(2) (p<0.001).
    2 context sentences
    Summary · context
    The study included 245 subjects.
    Summary · context
    They received liraglutide in addition to their usual dual therapy (metformin and sulfonylureas or pioglitazone).
  4. 04HumanObservational studyOther

    At 12 months, most patients received liraglutide 1.2 mg/day, a third received 1.8 mg and a few received 0.6 mg.

    In plain wordsAfter 12 months, most patients used liraglutide 1.2 mg a day, about a third used 1.8 mg, and few used 0.6 mg.

    Peptide
    Liraglutide
    Outcome
    Not applicableLiraglutide dose used at 12 months
    Study

    n = 245

    Outcome group
    Patterns of use · Pharmacology
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Patients on 1.2 mg/day
    64.6%
    12 months
    Patients on 1.8 mg
    32.7%
    12 months
    Patients on 0.6 mg
    2.7%
    12 months

    Source sentences

    Summary
    At 12 months, 64.6% of the patients received liraglutide at a dosage of 1.2 mg/day, 32.7% received 1.8 mg and 2.7% 0.6 mg.
    2 context sentences
    Summary · context
    The study included 245 subjects.
    Summary · context
    They received liraglutide in addition to their usual dual therapy (metformin and sulfonylureas or pioglitazone).
  5. 05HumanObservational studySafety outcome

    In adults with type 2 diabetes on dual therapy, adverse drug reactions occurred in 24% of patients on liraglutide.

    In plain wordsIn adults with type 2 diabetes, 24% of those on liraglutide had side effects linked to the drug.

    Peptide
    Liraglutide
    Outcome
    Not applicableAdverse drug reactions
    Study

    n = 245

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Patients with adverse drug reactions
    24%
    liraglutide

    Source sentences

    Summary
    Adverse drug reactions were present in 24% of subjects, most frequently gastrointestinal disorders (11.4%), mainly nausea (6.9%) and no pancreatic events.
    2 context sentences
    Summary · context
    The study included 245 subjects.
    Summary · context
    They received liraglutide in addition to their usual dual therapy (metformin and sulfonylureas or pioglitazone).
  6. 06HumanObservational studySafety outcome

    In adults with type 2 diabetes on dual therapy, gastrointestinal disorders were the most frequent adverse drug reactions with liraglutide (11.4%).

    In plain wordsIn adults with type 2 diabetes, stomach and gut problems were the most common side effects of liraglutide, in 11.4% of patients.

    Peptide
    Liraglutide
    Outcome
    Not applicableGastrointestinal disorders
    Study

    n = 245

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Patients with gastrointestinal disorders
    11.4%
    liraglutide

    Source sentences

    Summary
    most frequently gastrointestinal disorders (11.4%), mainly nausea (6.9%) and no pancreatic events.
    2 context sentences
    Summary · context
    The study included 245 subjects.
    Summary · context
    They received liraglutide in addition to their usual dual therapy (metformin and sulfonylureas or pioglitazone).
  7. 07HumanObservational studySafety outcome

    In adults with type 2 diabetes on dual therapy, nausea occurred in 6.9% of patients on liraglutide.

    In plain wordsIn adults with type 2 diabetes, 6.9% of those on liraglutide had nausea.

    Peptide
    Liraglutide
    Outcome
    Not applicableNausea
    Study

    n = 245

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Patients with nausea
    6.9%
    liraglutide

    Source sentences

    Summary
    mainly nausea (6.9%) and no pancreatic events.
    2 context sentences
    Summary · context
    The study included 245 subjects.
    Summary · context
    They received liraglutide in addition to their usual dual therapy (metformin and sulfonylureas or pioglitazone).
  8. 08HumanObservational studySafety outcome

    In adults with type 2 diabetes on dual therapy, no pancreatic events occurred with liraglutide.

    In plain wordsIn adults with type 2 diabetes on liraglutide, no pancreas problems were reported.

    Peptide
    Liraglutide
    Outcome
    No significant changePancreatic events
    Study

    n = 245

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    and no pancreatic events.
    2 context sentences
    Summary · context
    The study included 245 subjects.
    Summary · context
    They received liraglutide in addition to their usual dual therapy (metformin and sulfonylureas or pioglitazone).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT01288326

Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 254Feb 2011 to Mar 2013

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 26 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.